Type 2 diabetes

Weight loss concept
#Obesity #Roche #Type 2 diabetes #Weight loss #Zealand Pharma

Roche and Zealand drug shows 9.2% mean body weight reduction

Roche and Zealand Pharma have shared positive topline results from the Phase II ZUPREME-2 trial evaluating petrelintide versus placebo in people living with overweight or obesity and type 2 diabetes.  The trial met its primary endpoint, demonstrating that once-weekly subcutaneous injections of petrelintide (escalated every fourth week)… Read More

#News #Trending News

Weight loss tablets
#Eli Lilly #GLP-1 #MHRA #Obesity #Type 2 diabetes #Weight loss

UK first in Europe to authorise Lilly’s weight loss tablet orforglipron

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has authorised orforglipron (Foundayo), making it the first country in Europe to approve the GLP-1 tablet for both weight management and type 2 diabetes. Alongside a reduced-calorie diet and increased physical activity, orforglipron is authorised for weight loss and weight maintenance… Read More

#News #Regulatory

Boy tests his blood sugar levels at home
#GLP-1 #Novo Nordisk #Paediatrics #Phase III trial #Type 2 diabetes

Semaglutide could be first oral GLP-1 RA therapy for children

Positive topline results from Novo Nordisk’s PIONEER TEENS, a Phase IIIa trial evaluating oral semaglutide for type 2 diabetes demonstrated a superior reduction in HbA1c (a measure of blood sugar control) over placebo.  The trial, in children and adolescents aged 10–17 years with type 2 diabetes, also… Read More

#News

#Denmark #Drug development #Funding #Obesity #Pila Pharma #Type 2 diabetes #Weight loss

Biotech raises capital for new oral obesity treatment

Biotech company Pila Pharma has raised 20 million Swedish kronor ($2.08 million) in an almost fully covered capital raise, which includes a stock option for future use. Pila Pharma was founded by Danish researcher Dorte Gram, a former researcher at Novo Nordisk and was the first researcher to screen and… Read More

#Business & Investment #News

Human liver
#Liver disease #MetaVia #Type 2 diabetes

Novel GPR119 agonist shows promise in MASH and diabetes

MetaVia has announced that data from its Phase IIa clinical trial of DA-1241, a novel G-Protein-Coupled Receptor 119 (GPR119) agonist, in patients with presumed metabolic dysfunction-associated steatohepatitis (MASH), demonstrates both hepatoprotective and glucose-regulating effects. The data was presented in a late-breaking poster presentation at the European Association for the Study… Read More

#News

Woman tests blood glucose level
#AdipoPharma #Biotech #Clinical trials #France #Funding #Type 2 diabetes

Investments pave way for type 2 diabetes breakthrough 

French biotech AdipoPharma is developing a novel and promising type 2 diabetes drug, for which it has successfully secured the funding needed to begin Phase I clinical trials. The company expects to begin clinical trials in the US in mid-2025.     This funding will enable AdipoPharma to accelerate… Read More

#News

Woman tests blood glucose level
#Clinical trials #Diabetes #GLP-1 #Phesi #Type 2 diabetes

Increase in diabetes research fuelled by GLP-1s like Ozempic

Covid-19 is no longer in the top five most studied indications, replaced by type 2 diabetes, according to Phesi’s mid-year analysis of clinical trials. The analysis of 66,935 clinical trials reveals that the top five most studied diseases are now breast cancer, solid tumours, stroke, prostate… Read More

#News #Trending News

Ozempic Insulin injection pen
#Alzheimer's #Dementia #Nicotine addiction #Novo Nordisk #Type 2 diabetes

Could GLP-1 receptor agonists like Ozempic treat addiction and dementia?

Medications containing semaglutide such as Ozempic, licensed for diabetes, and Wegovy, for weight loss, are being studied to see if they can treat a range of different conditions, including addiction and dementia. Semaglutide manufacturer Novo Nordisk reported earlier this month that the drug reduces the risk… Read More

#News #Trending News

Ozempic box
#Adverse event #Diabetes #Drug safety #EMA #Type 2 diabetes

EMA reviews drug data relating to suicide risk

The European Medicines Agency (EMA) safety committee, the Pharmacovigilance Risk Assessment Committee (PRAC), is reviewing data on the risk of suicidal thoughts and thoughts of self-harm related to GLP-1 receptor agonists. The drugs under review include Ozempic (semaglutide), Saxenda (liraglutide) and Wegovy (semaglutide), used for weight… Read More

#News

Idiopathic intracranial hypertension
#Brain #Neuroinflammation #Neurology #Phase II trial #Type 2 diabetes #University of Birmingham

Type 2 diabetes drug could treat blinding IIH headaches

Patients with ‘blinding’ headaches known as idiopathic intracranial hypertension (IIH) could be treated with an injectable peptide used for type 2 diabetes, a new trial has found. The study was led by a team of neurologists from the University of Birmingham and University Hospitals Birmingham, and… Read More

#News #Trending News

Woman tests blood glucose level
#Atrogi #Clinical trial #Diabetes #Phase I trial #Start-ups #Type 2 diabetes

Start-up hopes novel drug could treat cause of type 2 diabetes

Swedish start-up Atrogi has enrolled the first patient in its Phase Ia/b study of ATR-258, a novel b2adrenoceptor agonist for the treatment of type 2 diabetes and comorbidities.  Conducted in Mannheim, Germany by Clinical Research Services (CRS), the trial is expected to be completed by April 2023… Read More

#News #Start-up Zone

Boy tests his blood sugar levels at home
#Boehringer Ingelheim #Eli Lilly #Paediatrics #Phase III trial #Type 2 diabetes

Positive Phase III trial data for SGLT2 inhibitor in type 2 diabetes

A Phase III trial has demonstrated that Jardiance (empagliflozin) is the first SGLT2 inhibitor to show a reduction in blood sugar levels in children and adolescents with type 2 diabetes.  The DINAMO Phase III clinical trial demonstrated a statistically significant reduction in HbA1c with empagliflozin compared with… Read More

#News

World Diabetes Day
#Diabetes #Drug discovery #Type 1 diabetes #Type 2 diabetes #World Diabetes Day

World Diabetes Day: Five drug discovery developments 

For World Diabetes Day, DDW’s Diana Spencer provides an overview of the latest innovations in the treatment of the disease. Here are 2022’s five most significant discoveries (in no particular order):  1. Human beta cell model Earlier this year, Human Cell Design, a biotechnology company focused on generating translational human… Read More

#Exclusive Content #News #Trending News

Girl testing blood glucose levels
#Diabetes #MHRA #Type 2 diabetes

New class of treatment approved for diabetic patients in the UK

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved a new class of treatment for adults with insufficiently controlled type 2 diabetes.  Marketing authorisation has been granted for Eli Lilly’s tirzepatide (Mounjaro), a once-weekly GIP (glucose-dependent insulinotropic polypeptide) receptor and GLP-1… Read More

#News

Patient using blood pressure monitor
#Cardiovascular disease #European Association for the Study of Diabetes #Type 2 diabetes

Analysis confirms cardiovascular benefits Ozempic

New trial data has shown consistent cardiovascular benefits from Novo Nordisk’s semaglutide in adults with type 2 diabetes, regardless of baseline blood sugar or kidney function. The results show that treatment with Ozempic (once-weekly semaglutide) or Rybelsus (oral semaglutide) demonstrated consistent reductions in major adverse cardiovascular events (MACE) compared with… Read More

#News

Diabetes patient injecting insulin
#Autoimmune disease #Biomedical research #Cardiovascular disease #Diabetes #Statins #Type 2 diabetes

Study: autoimmune disorders increase cardiovascular risk

Individuals with an autoimmune disorder have a substantially higher risk of developing cardiovascular disease, a large epidemiological study has revealed.  The research – led by KU Leuven in collaboration with colleagues in the UK, including the University of Glasgow, and published in The Lancet – shows for the first… Read More

#News